Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 27.67% is 11% above its 5-year average of 25.02%, near the low end of its 5-year range (16.24%–144.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.40% above its 12-month average of 25.77%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 27.67%.
RETURN ON EQUITY (ROE)
27.67%
RETURN ON EQUITY (ROE) AVG TTM
25.77%
RETURN ON EQUITY (ROE) AVG 3Y
24.63%
RETURN ON EQUITY (ROE) AVG 5Y
25.02%
RETURN ON EQUITY (ROE) AVG 10Y
51.15%
RETURN ON EQUITY (ROE) AVG 15Y
59.99%
RETURN ON EQUITY (ROE) AVG 20Y
55.01%
CURRENT VS TTM AVG
+7.40%
CURRENT VS 3Y AVG
+12.37%
CURRENT VS 5Y AVG
+10.62%
CURRENT VS 10Y AVG
-45.90%
CURRENT VS 15Y AVG
-53.87%
CURRENT VS 20Y AVG
-49.70%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+112.71%
vs the sector median at left
Market Cap
$101.46B
Return on Equity (ROE)
N/A
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$94.31B
Return on Equity (ROE)
N/A
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$104.41B
Return on Equity (ROE)
15.55%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$85.90B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$113.46B
Return on Equity (ROE)
10.41%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$113.72B
Return on Equity (ROE)
6.16%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$81.19B
Return on Equity (ROE)
13.65%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $98.65B | 27.67% | 25.77% | 24.63% | 25.02% |
| Sanofi (SNY)vs › | $98.71B | 5.82% | 9.06% | 9.15% | 10.86% |
| McKesson Corporation (MCK)vs › | $101.46B | N/A | -189.06% | -180.53% | 3473.86% |
| HCA Healthcare, Inc. (HCA)vs › | $94.31B | N/A | -171.53% | -210.62% | -155.29% |
| Stryker Corporation (SYK)vs › | $104.41B | 15.55% | 14.50% | 15.05% | 14.30% |
| Elevance Health Inc. (ELV)vs › | $85.90B | 11.06% | 13.69% | 14.71% | 14.93% |
| Medtronic plc (MDT)vs › | $113.46B | 10.41% | 9.71% | 8.51% | 8.44% |
| CVS Health Corp. (CVS)vs › | $113.72B | 6.16% | 4.23% | 6.35% | 7.74% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.19B | 13.65% | 14.72% | 15.95% | 23.11% |
| Moderna, Inc. (MRNA)vs › | $78.91B | -46.61% | -32.64% | -13.90% | 0.25% |
ROE
27.7%
ROA
7.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 27.67% |
| 2026-03-31 | 25.19% |
| 2025-12-31 | 34.74% |
| 2025-09-30 | 24.99% |
| 2025-06-30 | 16.24% |
| 2025-03-31 | 17.04% |
| 2024-12-31 | 18.96% |
| 2024-09-30 | 16.92% |
| 2024-06-30 | 21.92% |
| 2024-03-31 | 25.44% |
| 2023-12-31 | 28.32% |
| 2023-09-30 | 38.09% |
| 2023-06-30 | 86.60% |
| 2023-03-31 | 92.65% |
| 2022-12-31 | 134.48% |
| 2022-09-30 | 144.53% |
| 2022-06-30 | 25.79% |
| 2022-03-31 | 39.03% |
| 2021-12-31 | 22.70% |
| 2021-09-30 | 22.04% |
| 2021-06-30 | 20.22% |
| 2021-03-31 | 24.12% |
| 2020-12-31 | 26.73% |
| 2020-09-30 | 33.86% |
| 2020-06-30 | 40.22% |
| 2020-03-31 | 33.72% |
| 2019-12-31 | 29.64% |
| 2019-09-30 | 39.83% |
| 2019-06-30 | 124.26% |
| 2019-03-31 | 96.70% |
| 2018-12-31 | 98.57% |
| 2018-09-30 | 42.23% |
| 2018-06-30 | 46.08% |
| 2017-09-30 | 174.13% |
| 2017-06-30 | 231.24% |
| 2017-03-31 | 97.58% |
| 2016-12-31 | 85.94% |
| 2016-09-30 | 196.97% |
| 2016-06-30 | 15.48% |
| 2016-03-31 | 23.10% |
| 2015-12-31 | 166.03% |
| 2015-09-30 | 178.21% |
| 2015-06-30 | 135.09% |
| 2015-03-31 | 139.48% |
| 2014-12-31 | 67.63% |
| 2014-09-30 | 85.13% |
| 2014-06-30 | 75.28% |
| 2014-03-31 | 75.74% |
| 2013-12-31 | 75.00% |
| 2013-09-30 | 62.30% |
| 2013-06-30 | 64.00% |
| 2013-03-31 | 64.81% |
| 2012-12-31 | 76.49% |
| 2012-09-30 | 77.24% |
| 2012-06-30 | 73.47% |
| 2012-03-31 | 56.69% |
| 2011-12-31 | 66.59% |
| 2011-09-30 | 45.60% |
| 2011-06-30 | 37.08% |
| 2011-03-31 | 20.21% |
| 2010-12-31 | 18.24% |
| 2010-09-30 | 40.47% |
| 2010-06-30 | 48.43% |
| 2010-03-31 | 56.57% |
| 2009-12-31 | 54.10% |
| 2009-09-30 | 51.21% |
| 2009-06-30 | 57.39% |
| 2009-03-31 | 64.86% |
| 2008-12-31 | 73.37% |
| 2008-09-30 | 68.19% |
| 2008-06-30 | 67.09% |
| 2008-03-31 | 56.86% |
| 2007-12-31 | 54.76% |
| 2007-09-30 | 52.67% |
| 2007-06-30 | 48.75% |
| 2007-03-31 | 52.82% |
| 2006-12-31 | 54.17% |
| 2006-09-30 | 55.80% |
| 2006-06-30 | 55.81% |
| 2006-03-31 | 57.38% |
| 2005-12-31 | 67.24% |
| 2005-09-30 | 72.24% |
| 2005-06-30 | 74.58% |
| 2005-03-31 | 73.12% |
| 2004-12-31 | 71.45% |
| 2004-09-30 | 79.27% |
| 2004-06-30 | 76.67% |
| 2004-03-31 | 92.85% |
| 2003-12-31 | 54.03% |
| 2003-09-30 | 84.62% |
| 2003-06-30 | 53.60% |
